Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
NSTG > SEC Filings for NSTG > Form 8-K on 3-Jun-2014All Recent SEC Filings

Show all filings for NANOSTRING TECHNOLOGIES INC

Form 8-K for NANOSTRING TECHNOLOGIES INC


3-Jun-2014

Other Events, Results of Operations and Financial Condition, Financia


Item 8.01 Other Events.

On June 3, 2014, NanoString Technologies, Inc. ("NanoString" or the "Company") issued a press release announcing it had entered into a companion diagnostics collaboration with Celgene Corporation ("Celgene") under which the Company will support the development of Celgene's Revlimid for the treatment of Diffuse Large B-cell Lymphoma ("DLBCL") by developing an in vitro diagnostic assay that is intended to be used to enroll patients in a Phase III study of Revlimid for the treatment of a specific subtype of DLBCL. A copy of the press release announcing the Celgene collaboration is attached hereto as Exhibit 99.1 and is incorporated herein by reference.



Item 2.02 Results of Operations and Financial Condition.

The Company expects to begin recording revenue from the Celgene collaboration in the quarter ending June 30, 2014. Although the $5.75 million upfront payment and potentially other milestone payments will be received by the Company during 2014, the amount the Company records as revenue in 2014 is expected to be substantially less. The Company expects to recognize revenue over the entire development period in relation to the amount and timing of development related costs incurred. As a result, the Company expects a substantial portion of the cash received in 2014 to be deferred and recorded as revenue in future years. The Company currently expects that revenue recognized in 2014 related to the collaboration will be $2.0 million to $2.5 million.

The collaboration agreement with Celgene was executed in March 2014; however, agreements related to the underlying technology license and biological materials that are necessary for the Company's performance of its obligations under the collaboration were executed in May 2014. The Company's management considered the potential impact of the Celgene collaboration when 2014 revenue guidance was originally established in February. Accordingly, the Company does not believe any change to revenue guidance is warranted at this time. The Company's total revenue guidance for 2014 continues to be $45.0 million to $50.0 million. Pursuant to the rules and regulations of the Securities and Exchange Commission, the foregoing disclosure under Item 2.02 is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission.

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are identified by such words as "believe," "expect," "anticipate," "estimate," "plan," "may" and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company's plans, objectives, expectations and intentions. All statements other than historical or current facts, including, without limitation, statements about the successful development of an in vitro diagnostic assay; the receipt of future milestone payments, if any; the anticipated amount of revenue to be recorded related to the Celgene collaboration; and expectations regarding the Company's total revenues for 2014, are forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These statements, like all statements in this report, speak only as of their date.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

                   Exhibit
                   Number    Description

                    99.1     Press release dated June 3, 2014.


  Add NSTG to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for NSTG - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.